Introduction
Corticosteroids are used to treat a wide variety of disorders such as rheumatoid arthritis and systemic lupus erythematosis.10 Thus, an understanding of the inflammatory diseases and inhaled glucocorticoids have become the mainstay of modern asthma molecular and cellular mechanisms involved in SRA might identify key anti-inflammatory actions of stertherapy.1 Steroids reduce airway inflammation and improve lung function, and are the only drugs which oids and hence abnormalities underlying the chronic inflammatory process, in all these conditions. have been shown unequivocally to reduce nonspecific bronchial hyper-responsiveness (BHR) in Bronchial mucosal inflammation underpins asthma pathogenesis. CD4+ T lymphocytes play a pivotal asthma.2-5 The molecular mechanisms underlying this process are complex and not fully understood.
role in the propagation of antigen driven inflammatory responses through the recognition of class II Steroids exert their effects on inflammatory cells inter alia by regulating the transcription of target genes, MHC-peptide complexes by the CD3+/T-cell receptor (TCR) complex.11 This binding leads to lymphoeither directly or indirectly.6 However, a subset of asthmatics described as steroid-resistant (SRA), cyte activation with secretion of lymphokines which attract and activate eosinophils and mast cells.12 respond poorly to systemic or inhaled corticosteroids, and often require such high doses that the sideThere is increasing evidence to suggest that activated CD4+ T lymphocytes co-ordinate the inflammatory effects cause considerable morbidity.7 Corticosteroid resistance in asthma is not due to abnormal drug reaction observed in asthma.11 Poznansky et al.13, 14 showed that similar numbers of T-cell colonies were absorption or rapid elimination,7-9 and a similar lack of responsiveness to glucocorticoids is also observed observed when unfractionated PBMCs from SSA and SRA patients were cultured with the T-cell mitogen in patients suffering from other chronic inflammatory PHA in soft agar, in vitro. However, co-incubation Non-asthmatic subjects with methylprednisolone (10−8 M) produced a lower A group of five normal, healthy volunteers (aged degree of inhibition of colony formation in cells from 21-35 years) with no history of asthma or allergy the patients with SRA. This suggests an impairment were included as controls in the study. None of of the suppression of T-cell proliferation by glucothese subjects was taking any medication. corticoids, in these patients.
Corrigan et al. 9, 15 showed that PHA-induced proliferation of peripheral blood T cells was inhibited by harvester were from Wallac. Both CD4+ and/or CD8+ T cells might orchestrate the inflammation underlying asthma. The TH2 subset of CD4+ T cells produces IL-4 and IL-5, which not
CD4+ T-cell isolation
only switch B-cells to IgE production but also drive CD4+ T cells towards a TH2 phenotype. In contrast,
Isolation of PBMCs from blood samples

CD8+ T cells have recently been shown to switch
Peripheral blood mononuclear cells (PBMCs) were from IFNc production to IL-4 and IL-5 synthesis in isolated23 from whole-blood samples by density grathe presence of IL-4. 21 We investigated the sensitivity dient centrifugation over Ficoll. Peripheral venous of PHA-induced CD4+ T-cell proliferation22 to the blood was separated into 20 ml aliquots and made inhibitory effects of fluticasone propionate (FP) in up to 35 ml with 1×phosphate-buffered saline (PBS), SRA, and SSA, and compared it to that for CD8+ pH 7.4. Each 35 ml aliquot was layered over 15 ml T cells in the same patients and controls.
Ficoll in a 50 ml sterile tube. After centrifugation at 1200 g for 15 min at 20°C, PBMCs were removed from the plasma/Ficoll interface, transferred to a fresh sterile 50 ml Falcon tube and made up to 50 ml with
Methods
1×PBS. The PBMCs were pelleted by centrifugation
Patient selection
at 2000 g for 10 min at 20°C; the cells were washed twice with 50 ml 1×PBS and collected by centrifuFourteen adult asthmatic patients (5 males, 9 females, gation at 450 g for 5 min at 20°C. During subsequent aged 22-55 years) were studied, of whom six had experimental manipulations cells were maintained SSA and eight SRA. All patients had a >15% at 4°C. increase in FEV 1 following 200 mg inhaled salbutamol. In addition, the SSA patients had a >15%
Isolation of CD4+ T cells increase in FEV 1
following a 4-week therapeutic trial of inhaled FP at 2000 mg/day. In contrast, the SRA Isolated PBMCs were resuspended in 1 ml of 1×PBS at 4°C and Dynabeads M-450 CD4 were added to patients had a <15% improvement in FEV 1 after this trial, but a >15% increase in FEV 1 following 4 give a ratio of beads to target cells of 351. The cells were incubated with the Dynabeads for 60 min at weeks of FP at 4000-6000 mg/day. Two SRA patients were also taking 15 mg and 20 mg oral prednisolone/ 4°C on a rotary mixer. The beads were washed five times with 1×PBS/2% FCS, placing in a magneticday, respectively. Ethical approval for the study was provided by the Leeds (East) Medical Ethics particle concentrator (MPC) for 3 min between washes.24 Committee.
differing proportion of CD4+ and CD8+ T cells in
Separation of CD4+ T cells bound to
the T-lymphocyte population). Triplicate 100 ml ali-
Dynabeads with Detachabeads
quots of cells were transferred to a sterile flatDynabeads with bound CD4+ T cells were resusbottomed culture well plate for CD4+ T cells and pended in 100 ml of 1×PBS at 20°C in a 1.5 ml to a round-bottomed culture well plate for CD8+ T microcentrifuge tube and 1 unit of Detachabead Mcells (the lower surface area provided by this latter 450 CD4 was added. The tube was placed on a type of plate made it more suitable for CD8+ T rotary mixer for 60 min at 20°C and the volume cells, as 10 000 cells were added per well compared made up to 1 ml with 1×PBS. The tube was placed to 100 000 per well of CD4+ T cells). PHA was in a MPC for 3 min and the cell suspension transadded at a final concentration of 0.1 mg/ml (assays ferred to a 15 ml Falcon tube. The beads were at 0.1 and 1 mg/ml PHA produced identical results) washed twice with 1 ml 1×PBS and detached cells and FP was added at a concentration range of 10−10 were pelleted by centrifugation at 350 g for 5 min to 10−6 M. Recombinant IL-2 was included in the at 4°C.
CD8+ culture at 20 U/ml, since culturing without IL-2 did not result in proliferation of these cells.
Depletion of CD8+ T cells
Controls included were medium alone, and cells in The pelleted cells were resuspended in 1 ml, the absence of PHA. Culture plates were incubated 1×PBS/2% FCS at 4°C and 40 ml M-450 CD8
for 72 h in a humidified atmosphere at 37°C with Dynabeads added. After incubation at 4°C for 5% CO 2 . Cell proliferation was measured by the 30 min on a rotary mixer, 5 ml 1×PBS/2% FCS was uptake of [5-3H] thymidine (0.5 mCi) added for 18 h added to the cells. The Falcon tube was placed in a at the end of the 72-h incubation period. After MPC for 3 min and the supernatant removed. The incubation, cells were harvested onto a printed filter purified CD4+ T cells were pelleted by centrifugation mat using a cell harvester, and the incorporated for 5 min at 4°C, then resuspended in 3 ml 1×PBS.
tritiated thymidine was counted using a betaspectrometer (Betaplate). The results were expressed
CD8+ T-cell isolation
as mean corrected counts/min of triplicate cultures. The PBMC suspension depleted of CD4+ T cells was used in similar fashion to isolate CD8+ T cells
Statistical analysis
using Dynabeads M-450 CD8 and Detachabead MStatistical analysis used the Mann-Whitney U test.
Any contaminating CD4+ T cells were removed
A p value of 0.05 was considered significant for using Dynabeads M-450 CD4. The resulting purified each comparison. CD8+ cell population was resuspended in 2 ml 1×PBS.
Flow cytometry to check the purity of Figure 1 shows the degree of inhibition by FP, at varying concentrations (10−10 to 10−6 M), of PHATwo 50 ml aliquots of CD4+ or CD8+ T cells were induced proliferation of peripheral blood CD4+ T removed per sample, to check the purity of each lymphocytes, isolated from individuals in each of subpopulation of cells. To one 50 ml aliquot, 20 ml the three clinical groups studied. These results show each of MsIgG1-FITC, MsIgG1-RDI, and MsIgG1-an almost complete suppression of CD4+ T-lympho-ECD antibodies were added. To the second aliquot cyte thymidine uptake after PHA-stimulation in SSA of cells, anti-CD3-FITC, anti-CD4-RPE and anti-CD8-and non-asthmatic control subjects at a concentration ECD were added. The cells were stained for 1 h at of 10−9 M FP. Also, the mean IC 30 values for SSA 4°C in the dark and fixed with 500 ml fixing buffer and non-asthmatic subjects are lower than that for (1×PBS, 2% FCS, 2% normal human serum, 1%
Results
CD4+ and CD8+ T-cell preparations
SRA patients (Table 1 ). In CD4+ T cells from SRA sodium azide, 1% formalin). The purity of cells was patients, there was a reduction of only about 70% then determined by flow cytometry. Only cells at 10−8 M concentration, with no further reduction >98% pure were used in the study.
even at 10−6 M, compared to a reduction of about 95% in SSA patients and non-asthmatics (Table 2) .
Proliferation assay for CD4+ and CD8+
In contrast, the suppression of thymidine uptake
T cells
by FP in CD8+ T cells was identical in the three clinical groups. Absolute suppression of thymidine Purified CD4+ and CD8+ T cells were resuspended in RPMI-1640 medium, containing L-glutamine, 5% uptake was most consistent with the pattern seen in the CD4+ T cells from the SRA group (Figure 2 ). FCS and 1×penicillin/streptomycin, at 1×106 and 0.5×106 cells/ml, respectively (to account for the The IC 30 values of the three groups were around 6×10−10 M FP (Table 1) , with a reduction of only FP-mediated inhibition of PHA-induced T-cell proliferation in asthmatics, is the CD4+ T lymphocyte, 50% in thymidine uptake at 10−8 M FP (Table 2) . because the responses exhibited by CD8+ T cells Controls such as medium alone and cells in the remained constant across the various clinical categorabsence of PHA (counts of <100) did not show ies studied. Furthermore, under these experimental proliferation compared to cells+PHA (counts of conditions, CD8+ T cells were relatively unrespons1000s to 10 000s).
ive to steroids. The explanation for this is unclear, although it has been shown that in contrast to CD4+ T cells, CD8+ T lymphocytes show no significant Discussion changes in the expression of HLA-DR, CD45RA, Differences in the response to steroids after PHA-CD45RO and CD25 markers of activation, in stimulation of peripheral blood T cells, have previresponse to glucocorticoid therapy.25 Also, the perously been observed between SRA and SSA. It centages of CD8+ T cells expressing HLA-DR, CD45RA, and CD45RO in PBMCs from asthmatic appears that the primary site for this variability of patients were not significantly different to those in complete suppression of this induced proliferation, even at low doses of this drug. These results point the controls. Likewise, the percentages of CD25-expressing CD8+ T cells were only marginally elevto the CD4+ T cell as the more important target for steroid therapy in asthma and other inflammatory ated. 25 We therefore conclude that there is differential suppression of the proliferation of CD4+ T cells diseases. They also suggest that alternative therapeutic options should be considered when CD8+ T between SRA and SSA, by FP, while the proliferative responses of CD8+ T cells from both SSA and SRA cells are the major component of the inflammation present in a particular pathological condition. are relatively resistant to high doses of this drug. This points to the CD4+ T cell as the more important target for steroids in asthma. Although differential steroid suppression of proliferation of T-cell popula-
